Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung BioLogics IPO May Set Tone For Korean Biopharma Investors

Executive Summary

Samsung BioLogics has set out plans for one of the biggest ever IPOs in South Korea that could help reignite investor sentiment battered by recent events surrounding Hanmi.


Related Content

Biopharma Quarterly Dealmaking Statistics, Q4 2016
Korea To Limit Olmutinib Usage, Monitor All Patients
Korean Authorities Mull New Steps, Probe Over Olmutinib Events
Samsung BioLogics Eyes Global Leadership Via Korean IPO
BIO Korea 2016: SillaJen On Maximizing Value Of Pexa-Vec


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts